HiberCell

company

About

HiberCell is a clinical-stage biotechnology company dedicated to the advancement of novel therapeutic agents targeting adaptive stress.

  • 51 - 100

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
$30M
Industries
Biotechnology,Health Care,Health Diagnostics,Medical
Founded date
Jan 1, 2019
Number Of Employee
51 - 100
Operating Status
Active

HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis.

The company was founded in 2019 and is based in New York.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$158.15M
HiberCell has raised a total of $158.15M in funding over 2 rounds. Their latest funding was raised on May 19, 2021 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 19, 2021 Debt Financing $30M 1 Hercules Capital Detail
May 19, 2021 Series B $67.40M 1 Detail
Feb 7, 2019 Series A $60.75M 1 ARCH Venture Partners Detail

Investors

Number of Lead Investors
Number of Investors
2
2
HiberCell is funded by 2 investors. Hercules Capital and ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Debt Financing
ARCH Venture Partners Series B